Abstract
For fit patients with resectable NSCLC, surgery +/- adjuvant chemotherapy is standard of care. Despite this curative intent approach, rates of distant metastases are still substantial. To improve disease control, neoadjuvant administration of immune checkpoint inhibitors appears promising. Combining immune checkpoint inhibitors (anti PD-L1 and anti-CTLA-4) with chemotherapy and/or radiotherapy (RT) appears to further improve clinical efficacy, without unacceptable excess in toxicity. We hypothesize that neoadjuvant short course dual immunotherapy and medium dose RT improves both local and systemic disease control in resectable NSCLC with acceptable toxicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
